Zylox-Tonbridge to acquire German medical technology company Optimed
Optimed focuses on the global research, development, production, and distribution of devices for minimally invasive therapies.
19 January 2026
19 January 2026
Optimed focuses on the global research, development, production, and distribution of devices for minimally invasive therapies.
Genmab plans to present full results at an upcoming medical meeting.
Novartis intends to submit ianalumab for regulatory approval globally in early 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.